Skip to main content

Advertisement

Table 4 Multivariate analysis results (excluding Fludarabine/Busulfan-based conditioning regimens)

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

  Number Relative risk 95%CI
lower limit
95%CI
upper limit
p value
Acute GVHD (grades 3–4)a      
 Non-rituximab RIC 647 1    0.58
 Rituximab-containing RIC 356 0.89 0.59 1.34  
Chronic GVHD      
 Non-rituximab RIC 635 1    0.51
 Rituximab-containing RIC 349 1.07 0..87 1.30  
Non-relapse mortality      
 Non-rituximab RIC 638 1    0.14
 Rituximab-containing RIC 346 0.79 0.57 1.08  
Progression/relapse      
 Non-rituximab RIC 638 1    0.13
 Rituximab-containing RIC 346 0.82 0.64 1.06  
PFS      
 Non-rituximab RIC 638 1    0.002
 Rituximab-containing RIC 346 0.73 0.60 0.89  
Mortality      
 Non-rituximab RIC 662 1    0.02
 Rituximab-containing RIC 358 0.76 0.60 0.96  
  1. Abbreviations: GVHD graft-versus-host disease, RIC reduced-intensity conditioning
  2. aAcute GVHD models used logistic regression